News

Featured on Massive Science: how bit.bio's breakthrough opti-ox™ technology is being used by cultured meat company Meatable.

bit.bio wins Biotech Company of the Year at the Cambridge Independent Science andTechnology awards.

SynbioBeta CEO John Cumbers talks reimagining cell therapies through cell reprogramming with Rick Klausner and bit.bio CEO.

Dr Farah Patell-Socha, VP of Research Products discusses the launch of ioSkeletal Myocytes.

The first episode in our special three part mini-series.

IBI Journal Q&A with Dr Mark Kotter who talks about producing every human cell type at scale.

bit.bio CEO spoke about reprogramming human cells at the TEDxCambridgeUniversity ‘Untangling networks’ event.

Today Meatable announced their Series A fundraise of $47 million. Read about the connection to bit.bio.